MBX
NASDAQ HealthcareMBX Biosciences, Inc. - Common Stock
Biotechnology
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
�� 市场数据
| 价格 | $33.77 |
|---|---|
| 成交量 | 302,557 |
| 市值 | 1.60B |
| RSI（14日） | 64.8 |
| 200日均线 | $24.30 |
| 50日均线 | $32.37 |
| 52周最高 | $44.89 |
| 52周最低 | $7.20 |
| Forward P/E | -8.31 |
| Price / Book | 4.11 |
🎯 投资策略评分
MBX 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🐋 Institutional Whale (35/100) — 此策略 大盘、机构级别股票.
评分最低的策略： 🚀 Moon Shot (9/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 MBX in your text
粘贴任何文章、记录或帖子 — 工具将提取 MBX 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.